SCILEX HOLDING COMPANY - COMMON STOCK

Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

23 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region

17 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

02 Jul 2024 16:15:30 By Nasdaq GlobeNewswire

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

02 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024

01 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.

20 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)

14 Jun 2024 12:41:17 By Nasdaq GlobeNewswire

Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024

13 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies

11 Jun 2024 18:20:12 By Nasdaq GlobeNewswire

Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®

11 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.

10 Jun 2024 10:49:02 By Nasdaq GlobeNewswire

Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024

06 Jun 2024 13:56:09 By Nasdaq GlobeNewswire

Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company

30 May 2024 12:19:34 By Nasdaq GlobeNewswire

Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index

24 May 2024 12:40:58 By Nasdaq GlobeNewswire

Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company

24 May 2024 08:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®

14 May 2024 08:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

13 May 2024 08:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering

25 Apr 2024 15:01:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces $15 Million Registered Direct Offering

24 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses

16 Apr 2024 08:00:00 By Nasdaq GlobeNewswire